Recombinant Human CXCL7/PBP protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3690

---

Validation Data Gallery

• 

  Purity of Recombinant Human CXCL7 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CXCL7 protein Ala59-Asp128 (Accession# P02775) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 5473
• Accession: P02775
• PredictedSize: 34.8 kDa
• SDS-PAGE: 35-42 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Platelet basic protein (PBP) , slso named as NAP2, CXCL7, or β-Thromboglobulin, derived from its precursor pro-PBP (PPBP), is a platelet-derived growth factor that belongs to the CXC chemokine family, functioning as a potent chemoattractant and activator of neutrophils through binding to its receptor CXCR2. By post-translational cleavage, this small protein of ∼14 kD gives rise to connective tissue-activating peptide-III (CTAP-III), neutrophil-activating peptide-2 (NAP-2), β-thromboglobulin (β-TG), and two variants of thrombocidin (TC-1 and TC-2). High PPBP expression was significantly correlated with poor differentiation, lymph node metastasis, vascular invasion and advanced clinical stage.

References:

1. El-Gedaily A, et al. (2004). J Leukoc Biol. Mar;75(3):495-503. 
2. Kruidenier L, et al. (2006). Gastroenterology. Jan;130(1):127-36. 
3. Guo Q, et al. (2017). Oncol Rep. Feb;37(2):1114-1122.